Pfizer has been granted a new UK approval for its drug Inspra to be used for the treatment of cardiovascular mortality and morbidity in adult patients with chronic heart failure and left ventricular systolic dysfunction. The drug has been ratified for use in addition to standard optimal therapy after showing in clinical studies that it can cut the risk of cardiovascular death or heart failure hospitalisation by 37 percent among this patient group. Current heart failure treatment options have proven insufficient to prevent frequent hospitalisations and reduced life expectancy, causing distress for patients and incurring costs for the NHS.
